<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="15601"><DrugName>L-373890</DrugName><DrugSynonyms><Name><Value>L-373890</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>187162-33-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18077">Merck &amp; Co Inc</CompanyOriginator><CompaniesSecondary><Company id="18077">Merck &amp; Co Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15601" type="Drug"><TargetEntity id="247673" type="siDrug">L-373890</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="1076" type="ciIndication"><TargetEntity id="10043607" type="MEDDRA"/><TargetEntity id="D013927" type="MeSH"/><TargetEntity id="304" type="siCondition"/></SourceEntity><SourceEntity id="111" type="Action"><TargetEntity id="502" type="Mechanism">Thrombin Inhibitors</TargetEntity><TargetEntity id="4384" type="Mechanism">Anti-Thrombin</TargetEntity></SourceEntity><SourceEntity id="659" type="Action"><TargetEntity id="3176" type="Mechanism">Inhibitors of Blood Coagulation Pathways</TargetEntity></SourceEntity><SourceEntity id="PTGT-00713" type="ciTarget"><TargetEntity id="161932276721473" type="siTarget">Prothrombin</TargetEntity><TargetEntity id="1159" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="1076">Thrombosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="111">Factor IIa antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="659">Coagulation inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>B1E</Code><Name>DIRECT THROMBIN INHIBITORS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-19T05:41:57.000Z</LastModificationDate><ChangeDateLast>2005-12-06T11:05:26.000Z</ChangeDateLast><AddedDate>1997-07-30T13:33:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15601" linkType="Drug"&gt;L-373890&lt;/ulink&gt; is a pyridinone acetamide thrombin inhibitor, designed by &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt;. In vitro the compound showed 1000-fold greater selectivity for thrombin (Ki = 0.5 nM) than for trypsin (Ki = 570 nm) [&lt;ulink linkID="272401" linkType="reference"&gt;272401&lt;/ulink&gt;], [&lt;ulink linkID="252359" linkType="reference"&gt;252359&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;However, the compound is not sufficiently bioavailable to warrant further development [&lt;ulink linkID="283704" linkType="reference"&gt;283704&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1076">Thrombosis</Indication><StatusDate>1998-04-14T00:00:00.000Z</StatusDate><Source id="283704" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate>1997-07-30T13:33:24.000Z</StatusDate><Source id="252359" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00713"><Name>Factor IIa</Name><SwissprotNumbers><Swissprot>P00734</Swissprot><Swissprot>P00735</Swissprot><Swissprot>P18292</Swissprot><Swissprot>P19221</Swissprot><Swissprot>P84122</Swissprot><Swissprot>Q5R537</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cc1ccc(c(=O)n1CC(=O)NCC2CCN(CC2)C(=N)N)NS(=O)(=O)Cc3ccccc3</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1872448" number="WO-09701338" title="Pyridinone-thrombin inhibitors."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>